Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

175 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia.
Lozano ML, Mingot-Castellano ME, Perera MM, Jarque I, Campos-Alvarez RM, González-López TJ, Carreño-Tarragona G, Bermejo N, Lopez-Fernandez MF, de Andrés A, Valcarcel D, Casado-Montero LF, Alvarez-Roman MT, Orts MI, Novelli S, Revilla N, González-Porras JR, Bolaños E, Rodríguez-López MA, Orna-Montero E, Vicente V. Lozano ML, et al. Among authors: valcarcel d. Sci Rep. 2019 Nov 13;9(1):16680. doi: 10.1038/s41598-019-53209-y. Sci Rep. 2019. PMID: 31723222 Free PMC article.
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.
Platzbecker U, Della Porta MG, Santini V, Zeidan AM, Komrokji RS, Shortt J, Valcarcel D, Jonasova A, Dimicoli-Salazar S, Tiong IS, Lin CC, Li J, Zhang J, Giuseppi AC, Kreitz S, Pozharskaya V, Keeperman KL, Rose S, Shetty JK, Hayati S, Vodala S, Prebet T, Degulys A, Paolini S, Cluzeau T, Fenaux P, Garcia-Manero G. Platzbecker U, et al. Among authors: valcarcel d. Lancet. 2023 Jul 29;402(10399):373-385. doi: 10.1016/S0140-6736(23)00874-7. Epub 2023 Jun 10. Lancet. 2023. PMID: 37311468 Clinical Trial.
[Guidelines for diagnosis, treatment and monitoring of primary immune thrombocytopenia].
Sanz MÁ, Vicente García V, Fernández A, López MF, Grande C, Jarque I, Martínez R, Mingot ME, Monteagudo E, Ribera JM, Valcárcel D; Sociedad Española de Hematología y Hemoterapia; Sociedad Española de Hematología y Oncología Pediátricas. Sanz MÁ, et al. Among authors: valcarcel d. Med Clin (Barc). 2012 Mar 17;138(6):261.e1-261.e17. doi: 10.1016/j.medcli.2011.11.011. Epub 2012 Jan 16. Med Clin (Barc). 2012. PMID: 22257609 Spanish.
Updated experience with inolimomab as treatment for corticosteroid-refractory acute graft-versus-host disease.
García-Cadenas I, Valcárcel D, Martino R, Piñana JL, Novelli S, Esquirol A, Garrido A, Moreno ME, Granell M, Moreno C, Saavedra S, Briones J, Brunet S, Sierra J. García-Cadenas I, et al. Among authors: valcarcel d. Biol Blood Marrow Transplant. 2013 Mar;19(3):435-9. doi: 10.1016/j.bbmt.2012.11.012. Epub 2012 Nov 20. Biol Blood Marrow Transplant. 2013. PMID: 23178634 Free article.
Impact of hyperferritinemia on the outcome of reduced-intensity conditioning allogeneic hematopoietic cell transplantation for lymphoid malignancies.
Barba P, Valcárcel D, Pérez-Simón JA, Fernández-Avilés F, Piñana JL, Martino R, López-Anglada L, Rovira M, Garcia-Cadenas I, Novelli S, Carreras E, López Corral L, Sierra J. Barba P, et al. Among authors: valcarcel d. Biol Blood Marrow Transplant. 2013 Apr;19(4):597-601. doi: 10.1016/j.bbmt.2012.12.018. Epub 2013 Jan 8. Biol Blood Marrow Transplant. 2013. PMID: 23305680 Free article.
Impact of cyclosporine levels on the development of acute graft versus host disease after reduced intensity conditioning allogeneic stem cell transplantation.
García Cadenas I, Valcarcel D, Martino R, Piñana JL, Barba P, Novelli S, Esquirol A, Garrido A, Saavedra S, Granell M, Moreno C, Briones J, Brunet S, Sierra J. García Cadenas I, et al. Among authors: valcarcel d. Mediators Inflamm. 2014;2014:620682. doi: 10.1155/2014/620682. Epub 2014 Jan 30. Mediators Inflamm. 2014. PMID: 24623962 Free PMC article.
Multivariable time-dependent analysis of the impact of azacitidine in patients with lower-risk myelodysplastic syndrome and unfavorable specific lower-risk score.
Falantes J, Delgado RG, Calderón-Cabrera C, Márquez-Malaver FJ, Valcarcel D, de Miguel D, Bailén A, Bargay J, Bernal T, González-Porras JR, Tormo M, Ramos F, Andreu R, Xicoy B, Nomdedeu B, Brunet S, Sánchez J, Jurado AF, Bonanad S, Pérez-Simón JA, Sanz G; Spanish Group of Myelodysplastic Syndromes (GESMD). Falantes J, et al. Among authors: valcarcel d. Leuk Res. 2015 Jan;39(1):52-7. doi: 10.1016/j.leukres.2014.10.004. Epub 2014 Oct 30. Leuk Res. 2015. PMID: 25487012 Clinical Trial.
175 results